<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">Colorectal cancer</z:e> is one of the leading causes of <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e>-related <z:hpo ids='HP_0011420'>deaths</z:hpo> worldwide </plain></SENT>
<SENT sid="1" pm="."><plain>More than 30% patients present with <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastases</z:e> at diagnoses and will require systemic chemotherapy </plain></SENT>
<SENT sid="2" pm="."><plain>In recent years many anti-EGFR targets have been developed </plain></SENT>
<SENT sid="3" pm="."><plain>Among them, panitumumab, a fully human IgG2 monoclonal antibody has shown important benefits in the treatment of this disease </plain></SENT>
</text></document>